Antibodies to alpha-synuclein and uses thereof
AssigneeMedImmune, LLC
InventorsDarren Schofield, Michael Perkinton, Lorraine Irving, George Thom
Life of this patent
Estimating the term…
Abstract
The invention provides antibodies that specifically bind human α-synuclein with a high affinity and reduces α-synuclein spreading in vivo, recombinant polypeptides comprising said antibodies or antigen-binding fragment thereof and methods for generating such polypeptides, as well as compositions and methods for generating α-synuclein antibodies, and methods of using α-synuclein antibodies for the treatment of diseases of the central nervous system, in particular alpha-synucleinopathies.
Claims32
An antibody, or antigen-binding fragment thereof, that binds to human α-synuclein with a KD of less than 500 pM, specifically binds the region comprised between about amino acid 102 and about amino acid 130 within the C-terminal region of human α-synuclein, and reduces α-synuclein spreading in vivo.
2-20. (canceled)
An antibody, or antigen-binding fragment thereof that binds to human α-synuclein, wherein the antibody or antigen-binding fragment thereof comprises:
- a) three heavy chain CDRs having sequences:
- (i) H-CDR1 of SEQ ID NO:
- 5,
- (ii) H-CDR2 of SEQ ID NO:
- 15;
- and
- (iii) H-CDR3 of SEQ ID NO:
- 16, and
- b) three light chain CDRs having sequences:
- (i) L-CDR1 of SEQ ID NO:
- 20,
- (ii) L-CDR2 of SEQ ID NO:
- 10;
- and
- (iii) L-CDR3 of SEQ ID NO:
- 21.
26-29. (canceled)
42-45. (canceled)
47-48. (canceled)
Dependencies are inferred from the claim text.